Rare earth dual-mode fluorescent biological probe

Rare earth dual-mode fluorescent bioprobe developed by Fujian Institute of physics, Chinese Academy of Sciences at present, Chen Xueyuan group of the Key Laboratory of Optoelectronic Materials Chemistry and physics of Fujian Institute of physics, Chinese Academy of Sciences and Hong Maochun group of the State Key Laboratory of structural chemistry cooperate to adopt the design strategy of doping trivalent europium ion Eu3 into the inner and outer shells respectively, A core-shell-shell nano fluorescent probe based on Eu3 dual-mode (up conversion/down transfer) luminescence was successfully developed and successfully applied to the up conversion and dissolution enhanced down transfer luminescence dual-mode in vitro detection of alpha fetoprotein (AFP). The relevant research results were published in chemical science by the Royal Society of chemistry. It is reported that relevant technologies have applied for Chinese invention patents

afp, as a reliable tumor marker of primary liver cancer, is widely used in the early diagnosis of liver cancer and postoperative condition monitoring. Therefore, the ultra sensitive detection of AFP is of great significance for the diagnosis and treatment of primary liver cancer

it is reported that the detection limit of AFP up conversion detection of this new nano fluorescent probe is low. Many universal experimental machines have interchangeable dynamometers to 20 pg/ml, which is nearly 30 times higher than the sensitivity of commercial DELFIA kit. The imported original exchange digital controller controls the servo electromechanical matching step belt to make a pair of high-precision ball screw mobile test bench times, which is the lowest value of AFP detection based on rare earth nano probes so far. In addition, based on the dual-mode luminescence characteristics of Eu3, the research team proposed a new idea of using the dissolution enhanced transfer luminescence in vitro detection mode of the same nano probe as a self reference standard to evaluate the accuracy and reliability of its up conversion in vitro detection. The serum AFP levels of 20 cancer patients and normal people provided by tumor hospitals were measured, and the results were consistent with the commercial DELFIA kit, The specificity, accuracy and reliability of the detection method were verified by the determination of coefficient of variation and recovery of serum samples